Ocugen, Inc. (OCGN)

Clinical-stage biotech with an explicit going-concern warning in its latest SEC filings: recurring operating losses (net loss widened to $44.1M in H1 2026), negative book equity, and negative working capital after the May 2026 $130M convertible note issuance was classified as current pending a September 21, 2026 shareholder vote. A $100M cash balance, three BLA programs targeted by 2028, and a $5.00 analyst consensus target provide upside optionality, but distress metrics (Altman Z near -5.3, negative margins, negative free cash flow, negative DCF values) and heavy ongoing dilution make this a speculative, high-risk name.

Severe red-flag cap applied: Ocugen carries active going-concern substantial doubt (FY2025 10-K auditor explanatory paragraph, management conclusion reiterated in the Q2 2026 10-Q dated 2026-08-06). The tape is otherwise two-sided — the announced OCU410 Phase 3 ArMaDa3 first-patient-dosed catalyst is offset by the OCU410ST Stargardt DMC futility-consideration readout that drove a ~14% selloff on 2026-09-09 plus a fresh CEO 10b5-1 selling overhang, with sentiment delta deteriorating (baseline +0.24 → scoring ≈ +0.01).

Score 1 (bearish/broken structure). Price sits below SMA20/50/200 and EMA9/21 after a -18.3% catalyst-day breakdown on 38.9M shares (Stargardt readout, 2026-09-09); ADX14 44.4 confirms a strong trend that, with price under every moving average, is DOWN; MACD line has just crossed below signal (both near/below zero); Williams %R -97.5 and RSI14 29.4 are deeply oversold, which at most supports a reflex bounce, not a 1-15 day bullish swing. Oversold momentum is the only offset. Action is blocked regardless: fundamentalScore 1 and qualitativeScore 1 are below the required floor of 3, and this partial-run input carries no runDate source, so chart/event windows cannot be anchored to a trustworthy 'today' (stale-feed branch, score capped at 2).